AUPH Valuation

Aurinia Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

13.070

+0.07(0.538%)1D

Overview
Forecast
Valuation
Earnings

AUPH Relative Valuation

AUPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AUPH is overvalued; if below, it's undervalued.

Historical Valuation

Aurinia Pharmaceuticals Inc (AUPH) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 1.37. The fair price of Aurinia Pharmaceuticals Inc (AUPH) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：13.07

Fair

20.32

Trailing

Forward

12.08

EV/EBITDA

Aurinia Pharmaceuticals Inc. (AUPH) has a current EV/EBITDA of 12.08. The 5-year average EV/EBITDA is 2.10. The thresholds are as follows: Strongly Undervalued below -82.79, Undervalued between -82.79 and -40.34, Fairly Valued between 44.55 and -40.34, Overvalued between 44.55 and 86.99, and Strongly Overvalued above 86.99. The current Forward EV/EBITDA of 12.08 falls within the Historic Trend Line -Fairly Valued range.

14.24

EV/EBIT

Aurinia Pharmaceuticals Inc. (AUPH) has a current EV/EBIT of 14.24. The 5-year average EV/EBIT is -40.87. The thresholds are as follows: Strongly Undervalued below -377.68, Undervalued between -377.68 and -209.27, Fairly Valued between 127.54 and -209.27, Overvalued between 127.54 and 295.94, and Strongly Overvalued above 295.94. The current Forward EV/EBIT of 14.24 falls within the Historic Trend Line -Fairly Valued range.

6.01

Aurinia Pharmaceuticals Inc. (AUPH) has a current PS of 6.01. The 5-year average PS is 11.60. The thresholds are as follows: Strongly Undervalued below -11.35, Undervalued between -11.35 and 0.13, Fairly Valued between 23.07 and 0.13, Overvalued between 23.07 and 34.55, and Strongly Overvalued above 34.55. The current Forward PS of 6.01 falls within the Historic Trend Line -Fairly Valued range.

12.28

P/OCF

Aurinia Pharmaceuticals Inc. (AUPH) has a current P/OCF of 12.28. The 5-year average P/OCF is -7.19. The thresholds are as follows: Strongly Undervalued below -61.19, Undervalued between -61.19 and -34.19, Fairly Valued between 19.81 and -34.19, Overvalued between 19.81 and 46.81, and Strongly Overvalued above 46.81. The current Forward P/OCF of 12.28 falls within the Historic Trend Line -Fairly Valued range.

27.38

P/FCF

Aurinia Pharmaceuticals Inc. (AUPH) has a current P/FCF of 27.38. The 5-year average P/FCF is -3.62. The thresholds are as follows: Strongly Undervalued below -125.47, Undervalued between -125.47 and -64.54, Fairly Valued between 57.31 and -64.54, Overvalued between 57.31 and 118.23, and Strongly Overvalued above 118.23. The current Forward P/FCF of 27.38 falls within the Historic Trend Line -Fairly Valued range.

Aurinia Pharmaceuticals Inc (AUPH) has a current Price-to-Book (P/B) ratio of 5.17. Compared to its 3-year average P/B ratio of 2.99 , the current P/B ratio is approximately 73.11% higher. Relative to its 5-year average P/B ratio of 3.87, the current P/B ratio is about 33.48% higher. Aurinia Pharmaceuticals Inc (AUPH) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -2.10%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -4.07% , the current FCF yield is about -100.00% lower.

5.17

P/B

Median3y

2.99

Median5y

3.87

5.40

FCF Yield

Median3y

-2.10

Median5y

-4.07

Competitors Valuation Multiple

The average P/S ratio for AUPH's competitors is 0.00, providing a benchmark for relative valuation. Aurinia Pharmaceuticals Inc Corp (AUPH) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 22.41%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

AUPH.O

Aurinia Pharmaceuticals Inc

Twist Bioscience Corp

Intellia Therapeutics Inc

Cogent Biosciences Inc

Loss

1.75B

IMCR.O

Immunocore Holdings PLC

Celldex Therapeutics Inc

Loss

-70.78%

1.65B

Performance Decomposition

Market capitalization of AUPH increased by 78.31% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 1.26 to 30.73.

The secondary factor is the Revenue Growth, contributed 22.41%to the performance.

Overall, the performance of AUPH in the past 1 year is driven by Margin Expansion. Which is more sustainable.

22.41%

57.19M → 70.01M

Revenue Growth

2338.89%

1.26 → 30.73

Margin Expansion

-2282.99%

-1.42 → 31.09

P/E Change

78.31%